You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
Genes
Download PDF
  • Systematic Review
  • Open Access

1 October 2025

Genetic and Molecular Insights into Transforming Growth Factor-Beta Signaling in Periodontitis: A Systematic Review

and
1
Collegium Medicum, WSB University, 41-300 Dąbrowa Górnicza, Poland
2
PROTOM Dental, 32-500 Chrzanów, Poland
*
Author to whom correspondence should be addressed.
Genes2025, 16(10), 1165;https://doi.org/10.3390/genes16101165
This article belongs to the Section Molecular Genetics and Genomics
Version Notes
Order Reprints

Abstract

Background/Objectives: Transforming growth factor-beta (TGF-β) is a multifunctional cytokine involved in immune regulation, extracellular matrix turnover, and tissue repair. Its role in periodontitis remains controversial due to conflicting human studies. This systematic review addressed the PICO-based question: in adults with periodontitis (population), how does the expression and regulation of TGF-β isoforms (intervention/exposure) compare with healthy or post-treatment states (comparator) regarding clinical outcomes (outcomes)? Methods: A systematic search of PubMed and Scopus was conducted on 1 July 2025 for human studies published in English between 2010 and 2025. Eligible studies investigated TGF-β expression, function, or genetic regulation in periodontal tissues or biological fluids. Screening and quality appraisal were performed according to PRISMA guidelines, using design-specific risk-of-bias tools. The review protocol was prospectively registered in PROSPERO (CRD420251138456). Results: Fifteen studies met inclusion criteria. TGF-β1 was the most frequently analyzed isoform and was consistently elevated in diseased gingival tissue and gingival crevicular fluid, correlating with probing depth and attachment loss. Several studies reported post-treatment reductions in TGF-β, supporting its value as a dynamic biomarker. Additional findings linked TGF-β signaling to immune modulation, fibrosis, bone turnover, and systemic comorbidities. Evidence for TGF-β2 and TGF-β3 was limited but suggested isoform-specific roles in epithelial–mesenchymal signaling and scar-free repair. Conclusions: Current evidence supports TGF-β, particularly TGF-β1, as a central mediator of periodontal inflammation and repair, with promise as both a biomarker and therapeutic target. Standardized, isoform-specific, and longitudinal studies are needed to clarify its diagnostic and translational utility.

1. Introduction

Periodontitis is one of the most prevalent chronic inflammatory diseases worldwide and remains a major cause of tooth loss in adults. It is now understood not merely as a localized infection but as a complex, multifactorial condition initiated by dysbiotic biofilms and sustained by a dysregulated host immune–inflammatory response. This interplay leads to progressive destruction of the periodontal ligament and alveolar bone, ultimately compromising tooth support and oral function [,]. Beyond the oral cavity, periodontitis has been consistently associated with systemic disorders such as diabetes mellitus, cardiovascular disease, and chronic kidney disease, underscoring its relevance to general health [,,].
To improve diagnostic precision and international comparability, the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions introduced a staging and grading framework. Staging reflects the severity and extent of periodontal destruction, ranging from stage I (incipient disease) to stage IV (advanced disease with functional impairment), while grading estimates the rate of progression and risk factors, with grade A indicating slow progression, grade B moderate progression, and grade C rapid progression. This updated classification has become the global standard and emphasizes the need to integrate clinical, biological, and risk-related factors when evaluating periodontitis [].
Within this framework, attention has increasingly turned to molecular mediators such as transforming growth factor-beta (TGF-β), a pleiotropic cytokine []. In mammals, three isoforms—TGF-β1, TGF-β2, and TGF-β3—are expressed, with TGF-β1 being the most abundantly produced and studied in periodontal tissue []. The biological actions of TGF-β are mediated via a serine/threonine kinase receptor complex and subsequent activation of intracellular signaling cascades, primarily through the Mothers Against Decapentaplegic Homolog (SMAD)-dependent canonical pathway and alternative non-canonical pathways (e.g., mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase/protein kinase B (PI3K/AKT)). These pathways culminate in the regulation of gene expression involved in inflammation, extracellular matrix (ECM) remodeling, and cell differentiation [,,].
In the context of periodontitis, TGF-β plays a paradoxical role []. On one hand, it promotes the resolution of inflammation, supports the survival of periodontal ligament fibroblasts, and stimulates collagen synthesis and bone matrix deposition, thereby contributing to tissue repair and regeneration [,]. On the other hand, dysregulated or chronic activation of TGF-β signaling has been implicated in pathological fibrosis, aberrant immune responses, and osteoclastogenesis, which exacerbate periodontal destruction [,]. Moreover, recent studies suggest that TGF-β interacts with other key mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and receptor activator of nuclear factor κB ligand (RANKL), forming complex regulatory networks that influence disease outcome [].
Given the growing interest in TGF-β as a potential therapeutic target, especially in regenerative periodontal therapy and biomaterial engineering, it is crucial to comprehensively understand its role in the pathogenesis and progression of periodontitis [,,].
Despite the substantial body of literature, the findings regarding TGF-β in periodontitis remain heterogeneous and occasionally contradictory, owing to differences in study designs, patient populations, sampling techniques, and analytical methods. To date, no systematic review has comprehensively synthesized the current evidence on the role of TGF-β in periodontitis across molecular, cellular, and clinical levels.
Therefore, the objective of this systematic review was to critically evaluate and summarize current evidence on the role of TGF-β in periodontitis by explicitly addressing a PICO-based research question: in adult patients with periodontitis, what is the role of TGF-β isoforms compared with healthy or post-treatment conditions in relation to clinical severity, treatment outcomes, and systemic associations? In pursuing this aim, this review sought to integrate findings on differential isoform expression in human periodontal tissues and fluids to explore the regulatory mechanisms underlying TGF-β signaling at the molecular and genetic level and to determine the extent to which these pathways influence disease activity, response to therapy, and potential diagnostic or therapeutic applications.

2. Materials and Methods

2.1. Search Strategy

A systematic literature search was independently performed by two investigators (T.P. and B.O.G.) in PubMed and Scopus on 1 July 2025. The combined search yielded 11,601 records, of which 329 were from PubMed and 11,272 from Scopus. Search terms included multiple variants of transforming growth factor-beta combined with periodontal disease descriptors, for example, “transforming growth factor-beta,” “TGF-beta,” “TGF-β,” and “periodontitis” or “periodontal disease.” Initial filters were applied to restrict the dataset to articles published from 2010 onwards, original research studies, and adult human populations. The review protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration ID CRD420251138456).

2.2. Eligibility Criteria and Study Selection

We included original, peer-reviewed human studies published in English between 2010 and 2025 that investigated TGF-β in the context of periodontal disease. Eligible designs comprised randomized controlled trials (RCTs), cohort, case–control, cross-sectional, genetic association, and controlled pre–post studies. Adult participants (≥18 years) with periodontal conditions (e.g., gingivitis, chronic/aggressive periodontitis, chronic apical periodontitis) were eligible. Biological matrices included gingival tissue, gingival crevicular fluid (GCF), saliva, serum, alveolar bone, and periapical lesion tissues. Key outcomes were TGF-β isoform expression (protein or mRNA), associations with clinical indices (e.g., PI, GI, PPD, CAL), and pre–post therapeutic change. Exclusion criteria were non-human studies, in vitro-only work without human validation, reviews, editorials, conference abstracts, and non-English reports. We restricted inclusion to studies with free full-text availability to ensure full methodological transparency and reproducibility of data extraction and quality appraisal; this allowed verification of sampling, laboratory procedures, and statistical analyses beyond abstracts. The final dataset remained diverse in geography and design despite this restriction.
Two reviewers (T.P. and B.O.G.) independently screened titles, abstracts, and full texts for eligibility. Inter-rater agreement was quantified using Cohen’s kappa (κ = 0.82), indicating very good concordance. Any disagreements were subsequently resolved through discussion until consensus was reached.

2.3. Risk of Bias Assessment

Study quality was evaluated with validated, design-specific tools. Randomized controlled trials were appraised with the Cochrane risk of bias 2 (RoB 2) instrument [], which evaluates five domains: randomization process, adherence to interventions, missing outcome data, measurement of outcomes, and selective reporting. Observational and non-randomized studies, including cohort, case–control, cross-sectional, genetic association, and controlled pre–post designs, were assessed with a modified Newcastle–Ottawa scale (NOS), which considers selection, comparability, and outcome or exposure, with scores ranging from 0 to 9. For interpretability, scores were categorized as good (7–9), moderate (5–6), or poor (≤4) [].
Study quality was independently evaluated by the same two reviewers using design-specific tools. Agreement on risk of bias ratings was assessed with Cohen’s kappa (κ = 0.82), confirming very good inter-rater reliability. Any discrepancies in scoring were discussed until consensus was achieved.

2.4. Data Extraction and Synthesis (Added)

Because of considerable methodological heterogeneity across studies—including differences in study design, biological matrices (gingival tissue, GCF, serum, saliva, periapical tissue), analytical techniques (RT-qPCR, ELISA, immunohistochemistry), and reporting formats (absolute concentrations, relative expression, or categorical outcomes)—a formal meta-analysis was not feasible. In particular, inconsistent units of measurement, lack of standardized cut-off values, and variable post-treatment follow-up times precluded quantitative pooling. For these reasons, a narrative synthesis was performed. However, wherever possible, quantitative results were summarized descriptively to highlight patterns in biomarker expression and treatment-related changes. Data extraction was conducted independently by two reviewers (T.P. and B.O.G.) using a standardized extraction form piloted on three studies. Extracted variables included study design, population, biological sample, TGF-β isoform(s) analyzed, methods of detection, and main outcomes. Any discrepancies were resolved through consensus. No automation tools were used for data collection, “No formal assessment of reporting bias (e.g., funnel plots or Egger’s test) or certainty of evidence grading (e.g., GRADE) was conducted due to the small number and heterogeneity of included studies. This is acknowledged as a limitation.

3. Results

3.1. Study Selection

The initial database search identified 11,601 records related to TGF-β and periodontitis, with 329 retrieved from PubMed and 11,272 from Scopus. After removal of duplicates and application of eligibility filters—including publication year (2010 or later), study type (original research), and human adult populations—the pool of records was substantially reduced. In PubMed, 21 articles satisfied the inclusion requirements of being in English, freely accessible in full text, and conducted in adult participants. From Scopus, an initial set of more than ten thousand articles was progressively narrowed by full-text availability, language, and population criteria, leaving 575 studies for detailed review. Following full-text screening across both databases, 23 articles appeared eligible. After deduplication and exclusion of non-original designs, in vitro-only work, and animal studies, a total of 15 original human studies were retained for qualitative synthesis. These included two randomized controlled trials and thirteen observational or non-randomized studies. The selection process is summarized in the preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram (Figure 1).
Figure 1. PRISMA flow diagram of systematic review [].

Risk of Bias (Updated)

Among the two randomized controlled trials, one was judged to have overall low risk of bias, while the other was rated as having some concerns because of unblinded surgical interventions and unclear reporting due to absent preregistration. The thirteen observational or non-randomized studies achieved a median NOS score of 6 out of 9 (interquartile range 6–7), which indicates moderate to good quality. The most common limitations were small sample sizes, convenience sampling, and incomplete adjustment for potential confounders such as age, smoking, or comorbidities. In contrast, strengths included clear case definitions of periodontal disease and the use of standardized laboratory assays, particularly RT-qPCR, ELISA, and immunohistochemistry. Detailed study-level ratings are presented in Table 1 for randomized controlled trials and in Table 2 for observational studies.
Table 1. Cochrane Risk of Bias 2 (RoB 2) assessment of randomized controlled trials.
Table 2. NOS assessment of observational and non-randomized studies.

3.2. Characteristics of the Included Studies

The included studies were published between 2010 and 2025 and originated from multiple geographic regions, with Brazil contributing six studies, followed by the United States, Japan, China, and several European and Asian countries. Most investigations used cross-sectional designs, although interventional protocols and randomized controlled trials were also represented. A single study used a genetic association design to examine polymorphisms in the TGFB3 gene.
Study populations consisted of adults with chronic or aggressive periodontitis, gingivitis, or chronic apical periodontitis. Some studies also investigated patients with systemic comorbidities such as chronic kidney disease, reflecting the broader systemic associations of periodontal inflammation. To enhance internal validity, several investigations included comparison groups such as healthy controls, post-treatment patients, or individuals with clinically stable periodontal conditions.
The biological materials examined varied across studies. Gingival tissue and periodontal ligament were the most frequently analyzed, followed by gingival crevicular fluid, serum, saliva, and periapical lesion tissue. Nine studies explicitly quantified TGF-β1 expression at either the protein or mRNA level, while others reported findings for total TGF-β or examined downstream mediators. Only one study specifically addressed TGFB3 polymorphisms and their potential link to disease susceptibility (Table 3).
Table 3. Characteristics of the included studies.

4. Discussion

This systematic review synthesized evidence from original human studies investigating the involvement of transforming growth factor-beta (TGF-β) in the pathophysiology of periodontitis. Collectively, the findings highlight TGF-β—particularly TGF-β1—as a pivotal regulator of periodontal inflammation, extracellular matrix (ECM) remodeling, and wound-healing processes [,]. Elevated levels of TGF-β1 were consistently observed in gingival tissues and gingival crevicular fluid (GCF) of patients with chronic periodontitis, where they correlated with established clinical indices such as probing pocket depth (PPD), clinical attachment level (CAL), and plaque index (PI) [,]. Importantly, several studies demonstrated that TGF-β concentrations decrease after non-surgical periodontal treatment (NSPT) or surgical interventions, underscoring TGF-β’s potential role as a dynamic biomarker of therapeutic response [,,].
From a clinical perspective, TGF-β can be viewed as a mediator at the intersection of destructive inflammation and regenerative repair. Escobar et al. [] and Dengizek et al. [] reported that periodontal therapy not only improves clinical parameters but also significantly alters TGF-β expression profiles. Similarly, Sattari et al. [] observed postoperative reductions in GCF TGF-β1, consistent with the resolution of active inflammation. These findings suggest that monitoring TGF-β1 dynamics could aid clinicians in evaluating treatment efficacy and tailoring retreatment strategies. Beyond biomarker applications, regenerative studies provide evidence that TGF-β may actively contribute to repair. Liang et al. [], for instance, demonstrated that guided tissue regeneration combined with anchorage techniques enhanced TGF-β expression in GCF while reducing matrix-degrading factors, thereby promoting a regenerative environment. Such observations highlight the therapeutic potential of isoform-targeted approaches—for example, leveraging TGF-β3’s antifibrotic and pro-regenerative properties in periodontal tissue engineering.
Beyond local tissue effects, several studies emphasized the systemic relevance of TGF-β in patients with comorbid conditions. Rajaratinam et al. [] demonstrated that NSPT significantly reduced serum TGF-β1 and IL-6 in patients with chronic kidney disease, accompanied by improved renal function (eGFR). This underscores the potential bidirectional relationship between periodontal therapy, systemic inflammation, and organ health. In another context, Panezai et al. [] found correlations between serum TGF-β1 levels and periodontal status in rheumatoid arthritis patients, suggesting that systemic monitoring of TGF-β may have diagnostic or prognostic value across different inflammatory diseases. The functional relevance of TGF-β extends beyond biomarker dynamics. Toledo et al. [] and Popović et al. [] highlighted its role in shaping the Th17/Treg balance and in stabilizing chronic inflammatory lesions, consistent with the broader role of TGF-β in immune homeostasis. Da Costa et al. [] and Cirano et al. [] further linked TGF-β expression to tissue fibrosis and altered bone turnover in aggressive forms of periodontitis, suggesting that dysregulated signaling can promote pathological remodeling. Importantly, genetic variation may influence individual susceptibility. Gonçalves Junior et al. [] investigated TGF-β3 polymorphisms in Brazilian cohorts, showing that chronic periodontitis significantly increased peri-implantitis risk, although no direct association with TGFB3 variants was confirmed. These results argue for further isoform-specific genetic and epigenetic studies to elucidate host susceptibility patterns.
Although TGF-β1 dominated the included literature, isoform-specific biology suggests complementary roles for TGF-β2 and TGF-β3 in periodontal homeostasis and repair []. TGF-β2 has been implicated in epithelial–mesenchymal crosstalk, epithelial barrier integrity, and osteo-immune coupling, indicating a potential role at the interface of host defense and bone remodeling [,]. In contrast, TGF-β3 is repeatedly linked to scar-modulating, pro-regenerative signaling, and antifibrotic wound healing phenotypes that differ from TGF-β1 [,,]. Within our corpus, isoform-resolved clinical data for TGF-β2/β3 remain sparse; notably, one genetic association study did not find a significant relationship between a TGF-β-3 polymorphism and periodontitis or peri-implantitis, underscoring that isoform-specific effects may be context-dependent and subtle at the population level. Taken together, these observations argue for future isoform-resolved studies combining quantitative assays (active vs. latent protein forms), spatial profiling in gingival and bone compartments, and functional readouts (e.g., ECM turnover, osteoclastogenesis, Treg/Th17 balance) []. Such designs are essential to determine whether TGF-β-2 signals align more with mucosal protection and whether TGF-β-3 could be harnessed to bias healing toward antifibrotic, regenerative outcomes in periodontitis.
From a biomarker perspective, TGF-β—particularly TGF-β-1—behaves as a dynamic marker of disease activity and treatment response across matrices (GCF, saliva, serum, tissue). Before clinical adoption, three prerequisites are needed: (i) assay standardization (active vs. latent forms, kit/vendor, calibration, pre-analytics, normalization), (ii) matrix-specific reference ranges and analytical cut-offs established in multicenter cohorts, and (iii) evaluation within multimarker panels (e.g., TGF-β with IL-6, MMP-8, RANKL/OPG) to improve discrimination beyond single-analyte performance. Practical use cases include risk stratification at baseline, monitoring response after non-surgical therapy or surgery, and supporting decisions for retreatment [,].
Therapeutically, global TGF-β inhibition may carry off-target risks given its central homeostatic roles. More plausible strategies for periodontology are context- and isoform-targeted: (i) local delivery (e.g., GTR membranes, hydrogels, microspheres) to confine exposure; (ii) pro-regenerative biasing with TGF-β-3 to reduce fibrosis and improve matrix architecture in intrabony defects; and (iii) pathway-selective modulation (e.g., canonical vs. non-canonical SMAD/MAPK nodes) to uncouple repair from pro-fibrotic signaling. Early-phase trials should incorporate pharmacodynamic biomarkers (local TGF-β activity, ECM turnover markers) and safety readouts to define therapeutic windows [,,,].
In summary, the reviewed literature consistently supports the central role of TGF-β—predominantly TGF-β1—as a multifaceted mediator of periodontal disease progression and resolution [,]. Its expression levels were found to correlate with clinical severity, treatment response, systemic inflammatory burden, and, in some cases, genetic predisposition. These data reinforce the utility of TGF-β as both a biomarker of disease activity and a potential therapeutic target for modulating host responses in periodontitis [,].
We acknowledge that the restriction to PubMed and Scopus, as well as to English-language and freely accessible full-text publications, may introduce both language and publication bias and limit the comprehensiveness of the review. Important studies indexed in Embase, Web of Science, or the Cochrane Library and non-English articles could therefore have been overlooked. Expanding future searches to include additional databases and incorporating studies in other languages with appropriate translation support would improve the breadth and representativeness of the evidence base.
Beyond these search-related issues, several additional limitations must be considered. Considerable heterogeneity in study designs, population characteristics, and detection methods (e.g., RT-qPCR, ELISA, immunohistochemistry) complicates direct comparisons. Many investigations relied on systemic samples such as serum, which may not fully reflect local tissue-level activity, while the lack of standardized diagnostic criteria for periodontal disease further weakened cross-study comparability. The overwhelming focus on TGF-β1 has left the roles of TGF-β2 and TGF-β3 largely underexplored, despite their potential contributions to periodontal biology. Moreover, most studies were cross-sectional or short-term, limiting insight into longitudinal changes and long-term treatment outcomes. Although several included studies provided quantitative biomarker data, methodological heterogeneity in assay types, reporting standards, and clinical outcome measures prevented meaningful statistical pooling. Consequently, only a narrative synthesis was conducted. We did not formally assess reporting biases or certainty of evidence (GRADE). Therefore, the overall strength of the evidence should be interpreted cautiously, particularly given the modest number of included studies and their methodological heterogeneity.
Future research should therefore integrate both experimental and clinical approaches. Experimental directions include isoform-specific profiling of TGF-β activity (distinguishing active vs. latent forms), multi-omics approaches to map downstream signaling networks (SMAD vs. MAPK/PI3K/AKT pathways), and the development of biomaterials for localized, controlled release of TGF-β modulators. Clinically, longitudinal studies should evaluate TGF-β as a chairside biomarker in saliva or GCF, with standardized cut-offs and assay harmonization. TGF-β should also be tested within multimarker diagnostic panels alongside IL-6, MMP-8, or RANKL/OPG to enhance predictive accuracy. Finally, translational trials of isoform-targeted strategies—such as TGF-β3 supplementation to reduce fibrosis or selective SMAD/MAPK modulation—may provide novel therapeutic avenues in periodontology. Importantly, such approaches should include safety assessments, given the pleiotropic and systemic functions of TGF-β.

5. Conclusions

The current evidence demonstrates that TGF-β, particularly TGF-β1, is consistently elevated in periodontal disease and correlates with clinical indices of severity. Its levels respond dynamically to therapy, underscoring its potential value as a biomarker for disease monitoring and treatment evaluation. At the same time, functional studies indicate that TGF-β is not merely a marker but an active regulator of immune balance, extracellular matrix remodeling, and tissue repair within the periodontal microenvironment. Importantly, the dual nature of TGF-β—as both a pro-regenerative and pro-fibrotic factor—suggests that its therapeutic targeting must be carefully context-specific. Isoform-selective approaches, especially those harnessing the antifibrotic and regenerative potential of TGF-β3, may offer novel strategies to enhance periodontal regeneration while minimizing pathological fibrosis. However, before clinical translation can be realized, several challenges must be addressed: assay standardization, establishment of reference ranges in saliva and GCF, integration into multimarker diagnostic panels, and validation in longitudinal and multicenter cohorts. Additionally, the roles of TGF-β2 and TGF-β3, as well as genetic and epigenetic modifiers of TGF-β signaling, remain underexplored. In conclusion, TGF-β represents both a promising biomarker and a potential therapeutic target in periodontitis. Its incorporation into future diagnostic tools and regenerative therapies will depend on isoform-specific investigations, translational trials, and rigorous methodological harmonization. By bridging molecular insights with clinical application, TGF-β may ultimately contribute to more precise diagnosis, improved monitoring, and innovative treatment strategies in periodontology.

Author Contributions

Conceptualization, T.P. and B.O.G.; methodology, T.P. and B.O.G.; writing—original draft preparation, T.P. and B.O.G.; writing—review and editing, T.P. and B.O.G.; supervision, B.O.G.; project administration, B.O.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The review protocol was prospectively registered with PROSPERO (CRD420251138456) and is publicly accessible at https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251138456 (accessed on 1 September 2025).

Data Availability Statement

All data generated or analyzed during this study are included in this published article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
AgPAggressive Periodontitis
BSPBone Sialoprotein
CALClinical Attachment Level
CBCTCone-Beam Computed Tomography
CCL4C-C Motif Chemokine Ligand 4
CCL20C-C Motif Chemokine Ligand 20
CKDChronic Kidney Disease
COL ICollagen Type I
CPChronic Periodontitis
CRPC-Reactive Protein
CTGF/CCN2Connective Tissue Growth Factor/Cellular Communication Network Factor 2
EBVEpstein-Barr Virus
eGFREstimated Glomerular Filtration Rate
ELISAEnzyme-Linked Immunosorbent Assay
FDRFalse Discovery Rate
GAPGeneralized Aggressive Periodontitis
GCFGingival Crevicular Fluid
GIGingival Index
GTRGuided Tissue Regeneration
HCMVHuman Cytomegalovirus
HPHealthy Patients
HtrA1High Temperature Requirement A Serine Peptidase 1
IHCImmunohistochemistry
IFN-γInterferon Gamma
ILInterleukin
IL-1βInterleukin-1 Beta
IL-6Interleukin-6
IL-8Interleukin-8
IL-10Interleukin-10
IL-17Interleukin-17
LAP TGF-β1Latency-Associated Peptide of TGF-β1
MAPKMitogen-Activated Protein Kinase
MMPMatrix Metalloproteinase
MMP-8Matrix Metalloproteinase-8
MMP13Matrix Metalloproteinase-13
NSPTNon-Surgical Periodontal Treatment
OCOsteocalcin
OPGOsteoprotegerin
OROdds Ratio
PDPeriodontal Disease
PEAProximity Extension Assay
PIPlaque Index/Peri-implantitis
PPDProbing Pocket Depth
PRISMAPreferred Reporting Items for Systematic Reviews and Meta-Analyses
qRT-PCRQuantitative Real-Time Polymerase Chain Reaction
RARheumatoid Arthritis
RANKLReceptor Activator of Nuclear Factor κB Ligand
RCTRandomized Controlled Trial
SMADMothers Against Decapentaplegic Homolog (signaling proteins)
SRPScaling and Root Planing
TGFBTransforming Growth Factor Beta Gene
TGFB3Transforming Growth Factor Beta 3 Gene
TGF-βTransforming Growth Factor Beta
TGF-β1Transforming Growth Factor Beta 1
TGF-β3Transforming Growth Factor Beta 3
Th17T Helper 17 Cells
TIMP2Tissue Inhibitor of Metalloproteinases-2
TNF-αTumor Necrosis Factor Alpha
TregRegulatory T Cells

References

  1. Isola, G.; Polizzi, A.; Serra, S.; Boato, M.; Sculean, A. Relationship between Periodontitis and Systemic Diseases: A Bibliometric and Visual Study. Periodontology 2000 2025, in press. [Google Scholar] [CrossRef] [PubMed]
  2. Ray, R.R. Periodontitis: An Oral Disease with Severe Consequences. Appl. Biochem. Biotechnol. 2023, 195, 17–32. [Google Scholar] [CrossRef]
  3. Di Stefano, M.; Polizzi, A.; Santonocito, S.; Romano, A.; Lombardi, T.; Isola, G. Impact of Oral Microbiome in Periodontal Health and Periodontitis: A Critical Review on Prevention and Treatment. Int. J. Mol. Sci. 2022, 23, 5142. [Google Scholar] [CrossRef] [PubMed]
  4. Nascimento, G.G.; Alves-Costa, S.; Romandini, M. Burden of Severe Periodontitis and Edentulism in 2021, with Projections up to 2050: The Global Burden of Disease 2021 Study. J. Periodontal Res. 2024, 59, 823–867. [Google Scholar] [CrossRef]
  5. Liu, X.; Li, H. A Systematic Review and Meta-Analysis on Multiple Cytokine Gene Polymorphisms in the Pathogenesis of Periodontitis. Front. Immunol. 2021, 12, 713198. [Google Scholar] [CrossRef]
  6. Tonetti, M.S.; Greenwell, H.; Kornman, K.S. Staging and Grading of Periodontitis: Framework and Proposal of a New Classification and Case Definition. J. Periodontol. 2018, 89 (Suppl. 1), S159–S172. [Google Scholar] [CrossRef]
  7. Braczkowski, M.J.; Kufel, K.M.; Kulińska, J.; Czyż, D.Ł.; Dittmann, A.; Wiertelak, M.; Młodzik, M.S.; Braczkowski, R.; Soszyński, D. Pleiotropic Action of TGF-Beta in Physiological and Pathological Liver Conditions. Biomedicines 2024, 12, 925. [Google Scholar] [CrossRef]
  8. Chen, Y.; Wang, H.; Ni, Q.; Wang, T.; Bao, C.; Geng, Y.; Lu, Y.; Cao, Y.; Li, Y.; Li, L.; et al. B-Cell-Derived TGF-Β1 Inhibits Osteogenesis and Contributes to Bone Loss in Periodontitis. J. Dent. Res. 2023, 102, 767–776. [Google Scholar] [CrossRef]
  9. Giarratana, A.O.; Prendergast, C.M.; Salvatore, M.M.; Capaccione, K.M. TGF-β Signaling: Critical Nexus of Fibrogenesis and Cancer. J. Transl. Med. 2024, 22, 594. [Google Scholar] [CrossRef] [PubMed]
  10. Tie, Y.; Tang, F.; Peng, D.; Zhang, Y.; Shi, H. TGF-Beta Signal Transduction: Biology, Function and Therapy for Diseases. Mol. Biomed. 2022, 3, 45. [Google Scholar] [CrossRef]
  11. Yoshimoto, T.; Fujita, T.; Kajiya, M.; Matsuda, S.; Ouhara, K.; Shiba, H.; Kurihara, H. Involvement of Smad2 and Erk/Akt Cascade in TGF-Β1-Induced Apoptosis in Human Gingival Epithelial Cells. Cytokine 2015, 75, 165–173. [Google Scholar] [CrossRef] [PubMed]
  12. Wu, M.; Wu, S.; Chen, W.; Li, Y.-P. The Roles and Regulatory Mechanisms of TGF-β and BMP Signaling in Bone and Cartilage Development, Homeostasis and Disease. Cell Res. 2024, 34, 101–123. [Google Scholar] [CrossRef] [PubMed]
  13. Guo, C.; Rizkalla, A.S.; Hamilton, D.W. FGF and TGF-β Growth Factor Isoform Modulation of Human Gingival and Periodontal Ligament Fibroblast Wound Healing Phenotype. Matrix Biol. 2025, 136, 9–21. [Google Scholar] [CrossRef] [PubMed]
  14. Banlue, A.; Kaewmuangmoon, J.; Janebodin, K.; Tansriratanawong, K. Induction of Migration and Collagen Synthesis in Human Gingival Fibroblasts Using Periodontal Ligament Stem Cell Conditioned Medium. Eur. J. Dent. 2024, 18, 219–227. [Google Scholar] [CrossRef]
  15. Han, N.; Liu, Y.; Du, J.; Xu, J.; Guo, L.; Liu, Y. Regulation of the Host Immune Microenvironment in Periodontitis and Periodontal Bone Remodeling. Int. J. Mol. Sci. 2023, 24, 3158. [Google Scholar] [CrossRef]
  16. Huang, Y.; Tang, Y.; Zhang, R.; Wu, X.; Yan, L.; Chen, X.; Wu, Q.; Chen, Y.; Lv, Y.; Su, Y. Role of Periodontal Ligament Fibroblasts in Periodontitis: Pathological Mechanisms and Therapeutic Potential. J. Transl. Med. 2024, 22, 1136. [Google Scholar] [CrossRef]
  17. Mallick, S.; Duttaroy, A.K.; Bose, B. A Snapshot of Cytokine Dynamics: A Fine Balance Between Health and Disease. J. Cell Biochem. 2025, 126, e30680. [Google Scholar] [CrossRef]
  18. Huang, Y.; Zhang, L.; Tan, L.; Zhang, C.; Li, X.; Wang, P.; Gao, L.; Zhao, C. Interleukin-22 Inhibits Apoptosis of Gingival Epithelial Cells Through TGF-β Signaling Pathway During Periodontitis. Inflammation 2023, 46, 1871–1886. [Google Scholar] [CrossRef]
  19. Li, B.; Li, W.; Liao, Y.; Weng, Z.; Chen, Y.; Ouchi, T.; Fan, Y.; Zhao, Z.; Li, L. Multi-Omics Approach Reveals TGF-β Signaling-Driven Senescence in Periodontium Stem Cells. J. Adv. Res. 2024. [Google Scholar] [CrossRef]
  20. Plemmenos, G.; Evangeliou, E.; Polizogopoulos, N.; Chalazias, A.; Deligianni, M.; Piperi, C. Central Regulatory Role of Cytokines in Periodontitis and Targeting Options. Curr. Med. Chem. 2021, 28, 3032–3058. [Google Scholar] [CrossRef]
  21. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.-Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials. BMJ 2019, 366, l4898. [Google Scholar] [CrossRef]
  22. Norris, J.M.; Simpson, B.S.; Ball, R.; Freeman, A.; Kirkham, A.; Parry, M.A.; Moore, C.M.; Whitaker, H.C.; Emberton, M. A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research. Eur. Urol. 2021, 79, 325–326. [Google Scholar] [CrossRef]
  23. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
  24. Seydanur Dengizek, E.; Serkan, D.; Abubekir, E.; Aysun Bay, K.; Onder, O.; Arife, C. Evaluating Clinical and Laboratory Effects of Ozone in Non-Surgical Periodontal Treatment: A Randomized Controlled Trial. J. Appl. Oral Sci. 2019, 27, e20180108. [Google Scholar] [CrossRef]
  25. Liang, Y.; Zou, J.; Meng, X. Clinical Efficacy Analysis of Guided Tissue Regeneration Combined with Microscrew Implant Anchorage Technique in the Treatment of Periodontitis with Malocclusion. J. Investig. Surg. 2025, 38, 2507233. [Google Scholar] [CrossRef]
  26. Cirano, F.R.; Pimentel, S.P.; Ribeiro, F.V.; Casati, M.Z.; Casarin, R.C.; Gallafassi, D.F.; Nishii, D.; Corrêa, M.G. Impact of History of Periodontitis on Gene Expression of Bone-Related Factors in Young Patients. Braz Oral Res 2020, 34, e014. [Google Scholar] [CrossRef]
  27. Lorenz, T.; Niţulescu, E.A.; Zizzi, A.; Lorenzi, M.; Paolinelli, F.; Aspriello, S.D.; Baniţă, M.; Crăiţoiu, S.; Goteri, G.; Barbatelli, G.; et al. The Novel Role of HtrA1 in Gingivitis, Chronic and Aggressive Periodontitis. PLoS ONE 2014, 9, e96978. [Google Scholar] [CrossRef]
  28. Panezai, J.; Ghaffar, A.; Altamash, M.; Sundqvist, K.-G.; Engström, P.-E.; Larsson, A. Correlation of Serum Cytokines, Chemokines, Growth Factors and Enzymes with Periodontal Disease Parameters. PLoS ONE 2017, 12, e0188945. [Google Scholar] [CrossRef] [PubMed]
  29. Popović, J.; Cvetković, T.; Džopalić, T.; Stanković, A.; Nikolić, M.; Mitić, A.; Todorović, K.; Stošić, N.; Barac, R.; Milasin, J. Effects of Herpesviruses on Proinflammatory Cytokines in Chronic Periapical Lesions. Med. Sci. Monit. 2025, 31, e946843. [Google Scholar] [CrossRef]
  30. Rajaratinam, H.; Abdul Rahman, N.A.; Hanafi, M.H.; Zainuddin, S.L.A.; Ibrahim, H.A.; Kamarudin, M.I.; Wan Zain, W.M.S.; Kuttulebbai Nainamohamed Salam, S.; Isa, S.; Kassim, N.K. Exploring the Outcomes of Non-Surgical Periodontal Therapy in Modulating Periodontal Parameters, Renal Function, and Inflammatory Biomarkers in Chronic Kidney Disease Patients with Periodontitis. PeerJ 2025, 13, e19492. [Google Scholar] [CrossRef]
  31. Dessaune Neto, N.; Porpino, M.T.M.; Antunes, H.D.S.; Rodrigues, R.C.V.; Perez, A.R.; Pires, F.R.; Siqueira, J.F.; Armada, L. Pro-Inflammatory and Anti-Inflammatory Cytokine Expression in Post-Treatment Apical Periodontitis. J. Appl. Oral Sci. 2018, 26, e20170455. [Google Scholar] [CrossRef]
  32. Escobar, G.F.; Abdalla, D.R.; Beghini, M.; Gotti, V.B.; Rodrigues Junior, V.; Napimoga, M.H.; Ribeiro, B.M.; Rodrigues, D.B.R.; Nogueira, R.D.; Pereira, S.A.d.L. Levels of Pro and Anti-Inflammatory Citokynes and C-Reactive Protein in Patients with Chronic Periodontitis Submitted to Nonsurgical Periodontal Treatment. Asian Pac. J. Cancer Prev. 2018, 19, 1927–1933. [Google Scholar] [CrossRef]
  33. Gonçalves Junior, R.; Pinheiro, A.d.R.; Schoichet, J.J.; Nunes, C.H.R.; Gonçalves, R.; Bonato, L.L.; Quinelato, V.; Antunes, L.S.; Küchler, E.C.; Lobo, J.; et al. MMP13, TIMP2 and TGFB3 Gene Polymorphisms in Brazilian Chronic Periodontitis and Periimplantitis Subjects. Braz. Dent. J. 2016, 27, 128–134. [Google Scholar] [CrossRef]
  34. Honda, T.; Domon, H.; Okui, T.; Kajita, K.; Amanuma, R.; Yamazaki, K. Balance of Inflammatory Response in Stable Gingivitis and Progressive Periodontitis Lesions. Clin. Exp. Immunol. 2006, 144, 35–40. [Google Scholar] [CrossRef] [PubMed]
  35. Mize, T.W.; Sundararaj, K.P.; Leite, R.S.; Huang, Y. Increased and Correlated Expression of Connective Tissue Growth Factor and Transforming Growth Factor Beta 1 in Surgically Removed Periodontal Tissues with Chronic Periodontitis. J. Periodontal Res. 2015, 50, 315–319. [Google Scholar] [CrossRef] [PubMed]
  36. Sattari, M.; Fathiyeh, A.; Gholami, F.; Darbandi Tamijani, H.; Ghatreh Samani, M. Effect of Surgical Flap on IL-1β and TGF-β Concentrations in the Gingival Crevicular Fluid of Patients with Moderate to Severe Chronic Periodontitis. Iran. J. Immunol. 2011, 8, 20–26. [Google Scholar]
  37. Toledo, A.O.N.d.; Couto, A.M.d.; Madeira, M.F.M.; Caldeira, P.C.; Queiroz-Junior, C.M.; de Aguiar, M.C.F. Cytokines and Chemokines Associated with Treg/Th17 Response in Chronic Inflammatory Periapical Disease. Braz. Oral Res. 2019, 33, e093. [Google Scholar] [CrossRef]
  38. da Costa, T.A.; Silva, M.J.B.; Alves, P.M.; Chica, J.E.L.; Barcelos, E.Z.; Giani, M.A.A.; Garlet, G.P.; da Silva, J.S.; Rodrigues Júnior, V.; Rodrigues, D.B.R.; et al. Inflammation Biomarkers of Advanced Disease in Nongingival Tissues of Chronic Periodontitis Patients. Mediat. Inflamm. 2015, 2015, 983782. [Google Scholar] [CrossRef] [PubMed]
  39. Elebyary, O.; Barbour, A.; Fine, N.; Tenenbaum, H.C.; Glogauer, M. The Crossroads of Periodontitis and Oral Squamous Cell Carcinoma: Immune Implications and Tumor Promoting Capacities. Front. Oral Health 2020, 1, 584705. [Google Scholar] [CrossRef] [PubMed]
  40. Ioannou, P.; Katsoulieris, E.; Afratis, N.A. Matrix Dynamics and Microbiome Crosstalk: Matrix Metalloproteinases as Key Players in Disease and Therapy. Int. J. Mol. Sci. 2025, 26, 3621. [Google Scholar] [CrossRef]
  41. Dereka, X.E.; Markopoulou, C.E.; Vrotsos, I.A. Role of Growth Factors on Periodontal Repair. Growth Factors 2006, 24, 260–267. [Google Scholar] [CrossRef] [PubMed]
  42. Katsuno, Y.; Derynck, R. Epithelial Plasticity, Epithelial-Mesenchymal Transition, and the TGF-β Family. Dev. Cell 2021, 56, 726–746. [Google Scholar] [CrossRef] [PubMed]
  43. Liao, J.; Chen, R.; Lin, B.; Deng, R.; Liang, Y.; Zeng, J.; Ma, S.; Qiu, X. Cross-Talk between the TGF-β and Cell Adhesion Signaling Pathways in Cancer. Int. J. Med. Sci. 2024, 21, 1307–1320. [Google Scholar] [CrossRef]
  44. Moore, A.L.; Marshall, C.D.; Barnes, L.A.; Murphy, M.P.; Ransom, R.C.; Longaker, M.T. Scarless Wound Healing: Transitioning from Fetal Research to Regenerative Healing. Wiley Interdiscip. Rev. Dev. Biol. 2018, 7, e309. [Google Scholar] [CrossRef]
  45. Chang, Z.; Kishimoto, Y.; Hasan, A.; Welham, N.V. TGF-Β3 Modulates the Inflammatory Environment and Reduces Scar Formation Following Vocal Fold Mucosal Injury in Rats. Dis. Model. Mech. 2014, 7, 83–91. [Google Scholar] [CrossRef]
  46. Urban, L.; Čoma, M.; Lacina, L.; Szabo, P.; Sabová, J.; Urban, T.; Šuca, H.; Lukačín, Š.; Zajíček, R.; Smetana, K.; et al. Heterogeneous Response to TGF-Β1/3 Isoforms in Fibroblasts of Different Origins: Implications for Wound Healing and Tumorigenesis. Histochem. Cell Biol. 2023, 160, 541–554. [Google Scholar] [CrossRef]
  47. Boothe, D.L.; Coplowitz, S.; Greenwood, E.; Barney, C.L.; Christos, P.J.; Parashar, B.; Nori, D.; Chao, K.S.C.; Wernicke, A.G. Transforming Growth Factor β-1 (TGF-Β1) Is a Serum Biomarker of Radiation Induced Fibrosis in Patients Treated with Intracavitary Accelerated Partial Breast Irradiation: Preliminary Results of a Prospective Study. Int. J. Radiat. Oncol. Biol. Phys. 2013, 87, 1030–1036. [Google Scholar] [CrossRef]
  48. Khalaf, H.; Lönn, J.; Bengtsson, T. Cytokines and Chemokines Are Differentially Expressed in Patients with Periodontitis: Possible Role for TGF-Β1 as a Marker for Disease Progression. Cytokine 2014, 67, 29–35. [Google Scholar] [CrossRef]
  49. Danielpour, D. Advances and Challenges in Targeting Tgf-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective. Pharmaceuticals 2024, 17, 533. [Google Scholar] [CrossRef]
  50. Wang, X.; Zeng, J.; Gan, D.; Ling, K.; He, M.; Li, J.; Lu, Y. Recent Strategies and Advances in Hydrogel-Based Delivery Platforms for Bone Regeneration. Nanomicro Lett. 2024, 17, 73. [Google Scholar] [CrossRef] [PubMed]
  51. Sun, H.; Luan, J.; Dong, S. Hydrogels Promote Periodontal Regeneration. Front. Bioeng. Biotechnol. 2024, 12, 1411494. [Google Scholar] [CrossRef]
  52. Thielen, N.G.M.; van Caam, A.P.M.; Beuningen, H.M.V.; Vitters, E.L.; van den Bosch, M.H.J.; Koenders, M.I.; van de Loo, F.A.J.; Blaney Davidson, E.N.; van der Kraan, P.M. Separating Friend from Foe: Inhibition of TGF-β-Induced Detrimental SMAD1/5/9 Phosphorylation While Maintaining Protective SMAD2/3 Signaling in OA Chondrocytes. Osteoarthr. Cartil. 2023, 31, 1481–1490. [Google Scholar] [CrossRef] [PubMed]
  53. Mo, K.; Wang, Y.; Lu, C.; Li, Z. Insight into the Role of Macrophages in Periodontitis Restoration and Development. Virulence 2024, 15, 2427234. [Google Scholar] [CrossRef] [PubMed]
  54. Gürsoy, U.K.; Oikonomou, I.; Yilmaz, M.; Gürsoy, M. Advances in Periodontal Healing Biomarkers. Adv. Clin. Chem. 2025, 125, 143–167. [Google Scholar] [CrossRef] [PubMed]
  55. Yang, B.; Pang, X.; Li, Z.; Chen, Z.; Wang, Y. Immunomodulation in the Treatment of Periodontitis: Progress and Perspectives. Front. Immunol. 2021, 12, 781378. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
Genetic Parameters, Prediction of Genotypic Values, and Forage Stability in Paspalum nicorae Parodi Ecotypes via REML/BLUP
Previous
Crossroads of Iron Metabolism and Inflammation in Colorectal Carcinogenesis: Molecular Mechanisms and Therapeutic Perspectives
Next